Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116616) titled 'A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: ModernaTX, Inc.
Condition:
Relapsed or Refractory Multiple Myeloma
Intervention:
Drug: mRNA-2808
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: October 15, 2025
Target Sample Size: 166
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07116616
Publish...